Clinical Development of CT327, a novel treatment for childhood Atopic Dermatitis

CT327特应性皮炎(AD)项目旨在进一步开发Crebilis针对儿童AD的新型局部治疗方法。Crebilis是一家临床阶段的生物技术公司，开发皮肤病药物，拥有一支在将新药推向市场方面经验丰富的团队。我们打算在儿童AD中进一步开发CT327，这是一个重要且经常被忽视的未得到满足的医疗需求领域，需要有效但更安全的药物。我们相信CT327将满足这些需求。CT327有一种新的MOA，将治疗AD的所有症状，包括对生活质量影响最大的疾病的瘙痒成分。CT327使用Crebilis的低系统暴露(LSE)技术开发，在迄今进行的5项临床研究中具有良好的安全性。TSB的资助将使Creablis能够完成一项针对儿童的2b期AD研究，该研究将明确证明CT327的安全性和有效性特征，这将使CT327被定位为治疗儿童AD的新型长期局部疗法。

The CT327 Atopic Dermatitis (AD) project aims to further develop Creabilis' novel topical treatment for AD in children. Creabilis is a clinical stage biotech company developing drugs in dermatology, with a team experienced in bringing new drugs to market. We intend to further develop CT327 in childhood AD, an area of significant and often neglected unmet medical need, demanding effective, but safer drugs. We believe CT327 will meet these needs. CT327 has a novel MoA and will treat all symptoms of AD, including the itch component of the disease that has the greatest impact on quality of life. Developed using Creabilis’ Low Systemic Exposure (LSE) technology, CT327 has a favourable safety profile in the 5 clinical studies carried out to date. TSB funding will allow Creabilis to complete a Phase 2b AD study in children that will definitively demonstrate the safety and efficacy characteristics that will allow CT327 to be positioned as a novel long-term topical treatment for childhood AD.